Abstract: A method is provided that uses a server to dynamically configure software applications on an electronic device. Information is received from the device about the device (e.g. device OS, firmware version, make and/or model, etc.). The server determines based on the device information a set of capabilities of the device. The server then sends code for installation on the device to configure at least one of the software applications based on the determined capabilities of the device. A programmed server is also provided.

Abstract: Systems, methods, and computer storage media having computer-executable instructions embodied thereon that facilitates the presentation of list previews among search results are provided. Upon referencing a user query that indicates a user intent to view a list, a search result within a search results page is presented that includes a list preview. Such a list preview includes at least a portion of a list within a webpage that corresponds with the search results.

Abstract: The present invention provides compounds of Formula (I): and salts, racemates, isomers, diastereoisomers, enantiomers, hydrates, solvates, N-oxides, pharmaceutically acceptable derivatives or prodrugs thereof. Also provided the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

Abstract: A method is provided for evaluating a customer generated communication about a customer device. Terms of a customer generated communication are received with respect to the customer's device. Through a sentiment analysis engine, a sentiment expressed through the customer generated communication is determined. The sentiment has a sentiment strength, positive or negative. Through a parsing engine, an issue is extracted with respect to the device as expressed through the terms of the customer generated communication. A device profile of the device is retrieved, which has device parameters. Relevant device parameters to the extracted issue are determined, and these are forwarded to a rules engine. Through the rules engine, the extent to which the extracted issue is factually justified is verified. The extent of factual justification is correlated with the sentiment strength to arrive at a sentiment accuracy index.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

Abstract: The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom ? with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom ? with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

Abstract: The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom ? with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom ? with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims.

Abstract: A method is provided to enable a target device to be conformed with a reference device. After a peer-to-peer network connection is established between the target device and the reference device, profiles are taken of the target device and the reference device using diagnostic applications on the devices. The parameter values of the profiles are compared to establish a delta. Using this delta, at least one parameter value of the reference device profile is transmitted to the target device. That parameter value is automatically reset or adjusted to match or approximate the reference device profile. A method is also provided for using a first device to mediate the diagnosis and fixing of a second device.

Abstract: A method is provided for prioritizing rule creation for computer-assisted customer care. When a question from a user of a device is received by a customer care analytics engine for which no rule is automatically fired, the question and a related device profile of the device are added to an unfired questions list. The analytics engine parses the question to match terms in other questions in the list. The question is also added to an appropriate category in the list based on the device profile. A prioritization algorithm is used to rank the question among other questions within the list or the category, ranking the question more highly according to the frequency of those terms in the category or the list. According to its rank-wise order, the question is directed for creation of a rule to permit automatic handling of questions having the same or similar terms in the future.

Abstract: The present invention provides a compound of the following formula and salts thereof: Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

Abstract: A method is provided for providing customer care to a user of an electronic device. An information query package is created from text added by the user in a query about the electronic device, as well as, a device profile of the electronic device. The customer care case is automatically routed to an appropriate forum based on an analysis of the information query package. The forum selection may include screening for compatibility of the customer care case with a particular forum based on factors such as language, expertise and availability.

Abstract: A method is provided for augmenting a search query. Terms of a basic search query are received with respect to a user's device. A device profile of the device is retrieved. An augmented search query is formed by concatenating device parameters of the device profile with at least one of the terms of the basic search query. This augmented search query is then submitted to a search engine, and the results are displayed. A method of enhancing a device self-care session through an augmented search is also provided.

Abstract: Compounds of formula (I) have antibacterial activity: wherein R represents hydrogen or 1, 2 or 3 optional substituents; W is ?C(R1)—; R1 is hydrogen and R2 is hydrogen, methyl, or fluorine; or R1 and R2 taken together are —CH2—, —CH2CH2, —O—, or, in either orientation, —O—CH2— or —OCH2CH2—; and R3 is a radical of formula (Alk1)m-(Z)p-(Alk2)n-Q.

Abstract: A method is provided for determining a reference device profile. Device profiles are gathered from a plurality of devices having at least one characteristic in common. Each device profile has a plurality of parameter values. The device profiles are compared according to at least one device health metric. Parameter values associated with an optimum value of the device health metric are identified. Using these identified parameter values, a reference device profile is compiled. A method is also provided for enabling a target device to be conformed with a reference device profile.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyridyl-amino-pyrazine carbonitrile compounds that, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; and (e) ionizing radiation.

Abstract: A method is provided that uses a server to dynamically configure software applications on an electronic device. Information is received from the device about the device (e.g. device OS, firmware version, make and/or model, etc.). The server determines based on the device information a set of capabilities of the device. The server then sends code for installation on the device to configure at least one of the software applications based on the determined capabilities of the device. A programmed server is also provided.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to herein as “TFM compounds”) which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: The invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N?C(R6), (R7)C?N, (R8)N—C(O), (R8)2C—C(O), N?N or (R7)C?C(R6); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up to 3 heteroatoms selected from O, N and S; Q1 is a bond or a saturated C1-3 hydrocarbon linker group, one of the carbon atoms in the linker group being optionally be replaced by an oxygen or nitrogen atom, or an adjacent pair of carbon atoms may be replaced by CONRq or NRqCO where Rq is hydrogen or methyl, or Rq is a C1-4 alkylene chain linked to R or a carbon atom of Q1 to form a cyclic moiety; and wherein the carbon atoms of the linker group Q1 may optionally bear one or more substituents selected from fluorine and hydroxy; Q2 is a bond or a saturated hydrocarbon linker group containing from 1 to 3 carbon atoms, wherein one of the